AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12821730 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1.0 mU x kg(‐1) x min(‐1)) plus dextrose to maintain euglycemia
Number of subjects: 16
Study 12821730 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study 10587317 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish vaccine (normal dose, 0.05 ml) given to neonates at birth
Number of subjects: 0
Study 10587317 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish vaccine (half the normal dose) given at birth
Number of subjects: 0
Study 10587317 — intervention group
Group type: EXPERIMENTAL
Intervention: IRP vaccine given at birth at normal infant dose
Number of subjects: 0
Study 10587317 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish vaccine (normal infant dose) given at 3 months of age
Number of subjects: 0
Study 8561341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 20
Study 8561341 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (Control)
Number of subjects: 20
Study 1670113 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PAM (melphalan) or L-PAM plus fluorouracil
Number of subjects: 0
Study 1670113 — intervention group
Group type: COMPARATOR
Intervention: Untreated group from trial B-05
Number of subjects: 0
Study 1670113 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treated subgroups from four studies
Number of subjects: 0
Study 6120059 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg CZP nightly with no antacid
Number of subjects: 10
Study 6120059 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP nightly for 30 ml Maalox
Number of subjects: 10
Study 6120059 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP nightly with Maalox with an additional 30 ml Maalox three times daily
Number of subjects: 10
Study 6120059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antacid)
Number of subjects: 10
Study 30224529 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinfloxacin 400 mg
Number of subjects: 100
Study 30224529 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinfloxacin 600 mg
Number of subjects: 100
Study 30224529 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 100
Study 30224529 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinfloxacin (single and multiple doses)
Number of subjects: 100
Study 27229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 98
Study 27229713 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine + Epoetin-β
Number of subjects: 98
Study 27229713 — intervention group
Group type: EXPERIMENTAL
Intervention: SF3B1 mutation
Number of subjects: 98
Study 27229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of epigenetic mutation
Number of subjects: 98
Study 27229713 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal SNP array profile
Number of subjects: 98
Study 26274517 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric, aspheric Bi‐Flex T toric IOLs (Medicontur Medical Engineering Ltd., Inc.)
Number of subjects: 20
Study 24119130 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care pathway at University Medical Center Groningen
Number of subjects: 0
Study 24119130 — intervention group
Group type: COMPARATOR
Intervention: Care as usual in two other nonacademic hospitals
Number of subjects: 0
Study 21862748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-12/23 therapies (ustekinumab and briakinumab)
Number of subjects: 10183
Study 21862748 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α agents (adalimumab, etanercept, infliximab)
Number of subjects: 10183
Study 21862748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for anti-IL-12/23 therapies)
Number of subjects: 10183
Study 21862748 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for anti-TNF-α agents)
Number of subjects: 10183
Study 19065858 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion condition (apparent motion induced by a preceding neutral face image followed by an emotional face image)
Number of subjects: 0
Study 19065858 — intervention group
Group type: COMPARATOR
Intervention: Repetition condition (same emotional face image presented twice)
Number of subjects: 0
Study 16600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 740
Study 16600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + iron
Number of subjects: 740
Study 16600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid + iron + zinc
Number of subjects: 740
Study 16600929 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (folic acid, iron, zinc, and 11 other nutrients) + vitamin A
Number of subjects: 740
Study 16600929 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 740
Study 14651700 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music for 20 minutes daily
Number of subjects: 66
Study 14651700 — intervention group
Group type: COMPARATOR
Intervention: Sitting quietly for 20 minutes daily (Control)
Number of subjects: 66
Study 10981543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet rich in fruits, vegetables, low-fat dairy, whole grains, fish, poultry, and nuts; reduced in fats, red meats, sweets, and sugar-containing beverages for 8 weeks
Number of subjects: 133
Study 10981543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits-and-vegetables diet for 8 weeks
Number of subjects: 133
Study 10981543 — intervention group
Group type: COMPARATOR
Intervention: Control diet for 8 weeks
Number of subjects: 133
Study 9191677 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (XD)
Number of subjects: 43
Study 9191677 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 43
Study 9601228 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy
Number of subjects: 28
Study 9601228 — intervention group
Group type: COMPARATOR
Intervention: Myofunctional therapy and orthodontic appliances (e.g., activators)
Number of subjects: 28
Study 3515464 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-CO2
Number of subjects: 16
Study 3515464 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-HCl
Number of subjects: 16
Study 3515464 — intervention group
Group type: COMPARATOR
Intervention: Both bupivacaine-CO2 and bupivacaine-HCl
Number of subjects: 16
Study 30786846 — intervention group
Group type: COMPARATOR
Intervention: CF-ATL
Number of subjects: 3
Study 30786846 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-OTS
Number of subjects: 3
Study 30786846 — intervention group
Group type: COMPARATOR
Intervention: NPAC
Number of subjects: 3
Study 29330256 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin levels
Number of subjects: 5135
Study 29330256 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin concentrations
Number of subjects: 5135
Study 27595590 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (8‐12mg/day)
Number of subjects: 152
Study 27595590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 24875194 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 0.1 mg/kg per day
Number of subjects: 101
Study 24875194 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 0.3 mg/kg per day
Number of subjects: 101
Study 24875194 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 0.7 mg/kg per day
Number of subjects: 101
Study 24875194 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (up to 1.4 mg/kg per day)
Number of subjects: 101
Study 21810842 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin taken in the evening for 1 month
Number of subjects: 75
Study 21810842 — intervention group
Group type: COMPARATOR
Intervention: Aspirin taken in the morning for 1 month
Number of subjects: 75
Study 21810842 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin taken in the evening
Number of subjects: 75
Study 21810842 — intervention group
Group type: COMPARATOR
Intervention: Aspirin taken in the morning
Number of subjects: 75
Study 19952833 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (YG)
Number of subjects: 40
Study 18082451 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy
Number of subjects: 573
Study 18082451 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus radiotherapy (with MGMT assessment)
Number of subjects: 573
Study 18082451 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study 16841660 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) intervention
Number of subjects: 0
Study 16841660 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 14658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for speech
Number of subjects: 0
Study 14658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech self-efficacy
Number of subjects: 0
Study 14658994 — intervention group
Group type: COMPARATOR
Intervention: Fluent speakers (control group)
Number of subjects: 0
Study 14658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents who stutter
Number of subjects: 0
Study 10720532 — intervention group
Group type: EXPERIMENTAL
Intervention: OspA vaccine recipients
Number of subjects: 0
Study 10720532 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 0
Study 10720532 — intervention group
Group type: EXPERIMENTAL
Intervention: OspA vaccine recipients with Lyme disease
Number of subjects: 0
Study 8787872 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg
Number of subjects: 12
Study 8787872 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin 400 mg
Number of subjects: 12
Study 1465060 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-restricted diet
Number of subjects: 0
Study 1465060 — intervention group
Group type: COMPARATOR
Intervention: Normal protein intake
Number of subjects: 0
Study 3885456 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin E (n = 37)
Number of subjects: 73
Study 3885456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 73
Study 31012865 — intervention group
Group type: EXPERIMENTAL
Intervention: High confidence in prior attitudes
Number of subjects: 520
Study 31012865 — intervention group
Group type: EXPERIMENTAL
Intervention: High source credibility (+1 SD) with low confidence (-1 SD)
Number of subjects: 520
Study 31012865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tag popularity
Number of subjects: 520
Study 30223226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus goserelin (F + G)
Number of subjects: 138
Study 30223226 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin (A + G)
Number of subjects: 138
Study 30223226 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (G) alone
Number of subjects: 138
Study 27565964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 27565964 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 50
Study 24222323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocol
Number of subjects: 0
Study 21364931 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary trust game
Number of subjects: 0
Study 21364931 — intervention group
Group type: COMPARATOR
Intervention: Physical effort trust game
Number of subjects: 0
Study 16221299 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment (PST) provided by nurses
Number of subjects: 0
Study 16221299 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 12099989 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral oral solution diluted in apple juice
Number of subjects: 34
Study 12099989 — intervention group
Group type: COMPARATOR
Intervention: Neoral oral solution diluted in tap water
Number of subjects: 34
Study 9776153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative extraperitoneal instillation of bupivacaine
Number of subjects: 56
Study 8071496 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate diet (1.3 g protein/kg/day, 16-20 mg phosphorus/kg/day)
Number of subjects: 96
Study 8071496 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diet (0.575 g protein/kg/day, 5-10 mg phosphorus/kg/day)
Number of subjects: 96
Study 8071496 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low diet with keto or amino acids (0.28 g protein/kg/day, 4-9 mg phosphorus/kg/day)
Number of subjects: 96
Study 8071496 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (Moderate, Low, Very Low)
Number of subjects: 96
Study 8071496 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet diaries
Number of subjects: 96
Study 3378276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gentamicin and methicillin
Number of subjects: 20
Study 3378276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gentamicin and cloxacillin
Number of subjects: 20
Study 3378276 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and mezlocillin
Number of subjects: 20
Study 11595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction over 6 months
Number of subjects: 52
Study 11595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction over 12 and 24 months
Number of subjects: 52
Study 11595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain after initial weight loss
Number of subjects: 52
Study 11595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 52
Study 31630580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage and cervical pessary combined
Number of subjects: 75
Study 31630580 — intervention group
Group type: COMPARATOR
Intervention: Cervical cerclage alone
Number of subjects: 75
Study 31630580 — intervention group
Group type: COMPARATOR
Intervention: Cervical pessary alone
Number of subjects: 75
Study 31113531 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgisis anal fistula plug
Number of subjects: 304
Study 31113531 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's preference (e.g. fistulotomy, cutting seton, advancement flap, LIFT procedure)
Number of subjects: 304
Study 31113531 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's preference
Number of subjects: 304
Study 29859160 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg)
Number of subjects: 30
Study 29859160 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 27276165 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 56
Study 27276165 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250mg TID for 10 days) and physical therapy
Number of subjects: 56
Study 25386717 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR status (Do Not Resuscitate)
Number of subjects: 809
Study 25386717 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR status (Do Not Resuscitate) without withdrawal of life support
Number of subjects: 809
Study 25386717 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission severity of illness measured by APACHE III score
Number of subjects: 809
Study 22129488 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 2024
Study 22129488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis with rescue PCI
Number of subjects: 2024
Study 22129488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis with urgent/elective PCI
Number of subjects: 2024
Study 22129488 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis without PCI
Number of subjects: 2024
Study 22129488 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2024
Study 22129488 — intervention group
Group type: COMPARATOR
Intervention: No PCI during hospitalization
Number of subjects: 2024
Study 19829136 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyzene-F coated CATANIA stent
Number of subjects: 0
Study 19829136 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 19829136 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study 17879533 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and additional administering of arsenic trioxide (ATO)
Number of subjects: 74
Study 17879533 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy alone
Number of subjects: 74
Study 15898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 250 mg
Number of subjects: 30
Study 15898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 500 mg
Number of subjects: 30
Study 15898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stinoprate capsules 750 mg
Number of subjects: 30
Study 12480357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen/LDL apheresis
Number of subjects: 201
Study 12480357 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (250 mg prednisolone reduced by 25 mg per day, 500 mL 6% hydroxyethyl starch, 400 mg pentoxifylline per day)
Number of subjects: 201
Study 9659643 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (300 U/kg per dose, twice a week)
Number of subjects: 30
Study 9659643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7858363 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 3 ml saline) administered before the onset of pain (Group B)
Number of subjects: 90
Study 7858363 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (3 ml) administered before the onset of pain (Group A)
Number of subjects: 90
Study 7858363 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 3 ml saline) administered after the onset of pain (Group B)
Number of subjects: 90
Study 2576663 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 micrograms/h in 100 ml saline)
Number of subjects: 14
Study 2576663 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 14
Study 2576663 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 14
Study 818827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and isoniacid for 6 or 12 months
Number of subjects: 92
Study 818827 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 92
Study 31802697 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Body Image (HBI) intervention
Number of subjects: 2446
Study 31802697 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2446
Study 31553469 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy plus CBT
Number of subjects: 102
Study 31553469 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy plus CBT
Number of subjects: 102
Study 29168787 — intervention group
Group type: EXPERIMENTAL
Intervention: FRED game (exergame)
Number of subjects: 40
Study 29168787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 40
Study 25261425 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation group (18-32 minutes of pulsed current, stimulation frequency of 80 Hz, pulse duration of 200 μs, stimulation intensity fixed near the maximal tolerated)
Number of subjects: 45
Study 25261425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (electrical stimulation and low-level laser therapy)
Number of subjects: 45
Study 25261425 — intervention group
Group type: COMPARATOR
Intervention: Laser group (low-level laser therapy dose of 4-6 J per point, six points at the knee joint)
Number of subjects: 45
Study 24195208 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment with disperse-dense wave applied at specific acupuncture points (Taiyang, Xiaguan, Heliao)
Number of subjects: 68
Study 24195208 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment
Number of subjects: 68
Study 22053565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB) 1.25 mg/0.05 ml
Number of subjects: 60
Study 22053565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml
Number of subjects: 60
Study 22053565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab (IVB)
Number of subjects: 60
Study 22053565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Bevacizumab and Triamcinolone (IVB/IVT)
Number of subjects: 60
Study 19447807 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 260
Study 19447807 — intervention group
Group type: COMPARATOR
Intervention: Optimized anti-arrhythmic drug (AAD) therapy
Number of subjects: 260
Study 16510648 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable splint
Number of subjects: 113
Study 16510648 — intervention group
Group type: COMPARATOR
Intervention: Short arm cast
Number of subjects: 113
Study 15178990 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 1500
Study 15178990 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1500
Study 11269583 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric calf muscle training for 12 weeks
Number of subjects: 44
Study 11269583 — intervention group
Group type: COMPARATOR
Intervention: Concentric calf muscle training for 12 weeks
Number of subjects: 44
Study 9443527 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dose of diazepam
Number of subjects: 42
Study 9443527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9443527 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 8504712 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen patches (0.05 mg daily estradiol) with medroxyprogesterone acetate (5 mg orally for 14 days per month)
Number of subjects: 38
Study 8504712 — intervention group
Group type: COMPARATOR
Intervention: Calcium group (500 mg calcium daily)
Number of subjects: 38